文献速递肝病消化道肿瘤与早癌

瘦型MASLD长期预后:三项人群前瞻队列证据

Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts.
PubMed 文献 · Gut · 2026-03-06

BACKGROUND: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at increased risk of both hepatic and extrahepatic adverse outcomes. However, the evidence regarding lean MASLD and its prognosis remains controversial.…

要点

  • 瘦型MASLD肝脏相关事件风险是非瘦型的2.14倍(HR=2.14;95%CI 1.27-3.62)。
  • 瘦型MASLD全因死亡风险升高26%(HR=1.26;95%CI 1.14-1.39)。
  • 瘦型MASLD心血管疾病风险低于非瘦型(HR=0.89;95%CI 0.83-0.95)。

核心结论

  • 瘦型MASLD患者肝脏结局更差且全因死亡风险更高,但肝细胞癌和肝外癌症风险与非瘦型相当,心血管疾病风险更低。

研究设计与样本

  • 瘦型MASLD定义:开滦队列和中国慢性病前瞻性研究为BMI<23 kg/m²,英国生物银行为BMI<25 kg/m²。

主要发现

  • 瘦型MASLD肝脏相关事件风险HR=2.14(95%CI 1.27-3.62),全因死亡HR=1.26(95%CI 1.14-1.39)。
  • 瘦型MASLD肝脏相关死亡HR=2.31(95%CI 1.54-3.46),心血管死亡HR=1.22(95%CI 1.05-1.41)。
  • 瘦型MASLD肝细胞癌风险HR=1.76(95%CI 0.84-3.71),肝外癌症风险HR=1.14(95%CI 0.88-1.48)。
  • 瘦型MASLD心血管疾病风险HR=0.89(95%CI 0.83-0.95)。

临床怎么用

  • 瘦型MASLD患者应重视肝脏相关事件和死亡风险评估,而非仅关注体重。
  • 瘦型MASLD患者全因死亡和肝脏相关死亡风险更高,需加强随访管理。
  • 瘦型MASLD患者心血管疾病风险相对较低,但仍需关注心血管死亡风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at increased risk of both hepatic and extrahepatic adverse outcomes. However, the evidence regarding lean MASLD and its prognosis remains controversial. OBJECTIVE: To comprehensively investigate the long-term prognosis of lean patients with MASLD versus non-lean MASLD in Western and Asian populations. DESIGN: This prospective multicohort study included 153 192 patients with MASLD from UK Biobank (UKB), 29 700 from Kailuan cohort and 3329 from China Kadoorie Biobank (CKB). Lean MASLD was defined as body mass index (BMI)<23 kg/m² in Kailuan and CKB and <25 kg/m² in UKB. Primary endpoints were liver-related events (LREs), all-cause mortality, liver-related mortality (LRM), cardiovascular disease (CVD) mortality, CVD, hepatocellular carcinoma (HCC) and extrahepatic cancer. RESULTS: Overall, 181 191 non-lean and 5030 lean patients with MASLD were included. During a median of 14.2-year follow-up (median 14.1, 14.8 and 13.4 years in UKB, Kailuan and CKB), 2501 incident LREs, 22 482 all-cause deaths, 28 722 incident CVD cases, 326 HCC and 25 258 extrahepatic cancer cases were identified, with 375 LRM and 4511 CVD deaths. Pooled analysis of three cohorts showed lean MASLD had higher risks of LREs (HR=2.14; 95% CI 1.27 to 3.62), all-cause mortality (HR=1.26; 95% CI 1.14 to 1.39), LRM (HR=2.31; 95% CI 1.54 to 3.46) and CVD mortality (HR=1.22; 95% CI 1.05 to 1.41). By contrast, lean MASLD exhibited comparable HCC risk (HR=1.76; 95% CI 0.84 to 3.71) and extrahepatic cancer risk (HR=1.14; 95% CI 0.88 to 1.48), but reduced CVD risk (HR=0.89; 95% CI 0.83 to 0.95) versus non-lean MASLD. CONCLUSION: Lean patients with MASLD have worse liver outcomes and greater risk of all-cause mortality, but similar risk of HCC and extrahepatic cancer, and lower CVD risk.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Huo Z, Chen Y, Huang Y, et al. Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts. Gut. 2026. PMID: 41093635. doi:10.1136/gutjnl-2025-336127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。